Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
05/2003
05/13/2003US6562798 Immunostimulatory oligonucleotides with modified bases and methods of use thereof
05/13/2003US6562794 Cosmetic and dermatological formulations comprising flavonoids
05/13/2003US6562793 Antiallergic agent
05/13/2003US6562787 Hybrid polypeptides with enhanced pharmacokinetic properties
05/13/2003US6562784 Indications of mannan-binding lectin (MBL) in the treatment of immunocompromised individuals
05/13/2003US6562346 Fusion protein consisting of NS3, NS4 and NS5a polypeptides of hepatitus C virus with epitopes selected from sequence number 1 and/or 2
05/13/2003US6562345 Immuno-reactive peptide CTL epitopes of human cytomegalovirus
05/13/2003US6562343 Compositions and methods for the treatment and diagnosis of immune disorders
05/13/2003CA2467719A1 Anti-il-6 antibodies, compositions, methods and uses
05/13/2003CA2127876C Imidazole derivatives and their use as cytokine inhibitors
05/13/2003CA2086131C Anti-human ige monoclonal antibodies
05/08/2003WO2003038440A2 Chemokine binding molecules
05/08/2003WO2003038110A2 7118, a human arginine n-methyltransferase family member and uses therefor
05/08/2003WO2003038100A1 Methods and means for producing proteins with predetermined post-translational modifications
05/08/2003WO2003038058A2 Surfactant protein d for the prevention and diagnosis of pulmonary emphysema
05/08/2003WO2003038057A2 Genetic vaccine against human immunodeficiency virus
05/08/2003WO2003038052A2 Nucleic acid-associated proteins
05/08/2003WO2003038043A2 Combinations of dr5 antibody and other therapeutic agents
05/08/2003WO2003037921A1 Immunointeractive molecules and uses thereof
05/08/2003WO2003037916A2 Linear basic compounds having nk-2 antagonist activity and formulations thereof
05/08/2003WO2003037913A2 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
05/08/2003WO2003037899A1 Pde9 inhibitors for treating cardiovascular disorders
05/08/2003WO2003037898A1 Pyrimido [4,5-b] indole derivatives
05/08/2003WO2003037892A1 Compounds useful as reversible inhibitors of cysteine proteases
05/08/2003WO2003037879A1 Substituted (1h)-quinoxalin-2-one compounds and substituted 4-aryl- and 4-heteroarylcyclohexane compounds
05/08/2003WO2003037874A1 An efficient synthesis of 5-heteroatom-containing-pyrazoles
05/08/2003WO2003037873A1 Substituted benzo[b]azepin-2-one compounds
05/08/2003WO2003037863A2 Substituted indoles, method for production and use thereof for the inhibition of pain
05/08/2003WO2003037860A2 Purine analogs having hsp90-inhibiting activity
05/08/2003WO2003037852A1 Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
05/08/2003WO2003037433A1 Co-cycloalkyl 17-heteroaryl prostaglandin e2 analogs as ep2-receptor agonists
05/08/2003WO2003037384A2 Polymer conjugates of protein kinase c inhibitors
05/08/2003WO2003037377A1 Preventives/remedies for proliferative organ diseases, chronic arthritic diseases, hypertrophic scar or keloid
05/08/2003WO2003037376A1 Preventives and/or remedies for post-transplant arteriosclerosis as rejection of organ transplant
05/08/2003WO2003037371A2 Amp-kinase agonists or adenosine pro-drugs as immuno-stimulating agents
05/08/2003WO2003037366A1 Method of administering a thymosin alpha 1 peptide
05/08/2003WO2003037361A2 Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
05/08/2003WO2003037352A1 1-phenyl-5-n-heterocyclyl-pyrazoles as cyclooxygenase inhibitors for the treatment of inflammation associated disorders
05/08/2003WO2003037351A1 Heterocyclo-alkylsulfonyl pyrazoles and their use as cox-2 inhibitors
05/08/2003WO2003037350A1 New dry and aqueous epinastine-syrup-formulation
05/08/2003WO2003037349A1 Type 4 phosphodiesterase inhibitors and uses thereof
05/08/2003WO2003037339A1 Interferon $g(g) production promoter
05/08/2003WO2003037336A1 1-(5-sulfonyl-pyridin-2-yl)-5-(methylidene-cycloalkylmethoxy)-1h-pyrazole-4-carbonitrile derivatives and other compounds as cyclooxygenase inhibitors for the treatment of arthritis, neurodegeneration and colon cancer
05/08/2003WO2003037335A1 5-heteroatom-substituted pyrazoles
05/08/2003WO2003037330A1 Sulfonyl-and sulfonylheteroaryl-pyrazoles with a hydrazinyl or nitrogen oxide substituent at the 5-position for use as cyclooxygenase inhibitors
05/08/2003WO2003037321A1 Alkane diol derivatives as therapeutic agents for the treatment of bone conditions
05/08/2003WO2003037316A1 Peroxisome proliferator activated receptor ligands and process for producing the same
05/08/2003WO2003037308A2 Utilization of inhibitors of rho-kinases for stimulating nerve growth, inhibiting scar tissue formation and/or reducing a secondary lesion
05/08/2003WO2003037272A2 Thymosin alpha 1 peptide/polymer conjugates
05/08/2003WO2003037268A2 Hepta-, octa- and nonapeptides having antiangiogenic activity
05/08/2003WO2003037080A1 Nonhuman model animal of systemic lupus erythematosus
05/08/2003WO2003037079A1 NONHUMAN MODEL ANIMAL OF Th2-MEDIATED HYPERIMMUNE RESPONSE
05/08/2003WO2003014322A3 Proteins associated with cell growth, differentiation, and death
05/08/2003WO2003012105A3 Vegf isoform
05/08/2003WO2003002595A3 Dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents
05/08/2003WO2002098482A3 System for osmotic delivery of pharmaceutically active agents
05/08/2003WO2002090524A3 Isolated nucleic acid molecules encoding a novel human signal transducing kinase-mapkap-2; encoded proteins, cells transformed therewith and uses thereof
05/08/2003WO2002072608A3 POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW-AFFINITY FCηRECEPTORS
05/08/2003WO2002069985A3 Immune response potentiation
05/08/2003WO2002060897A3 Process for making substituted 8-arylquinolinium benzenesulfonate
05/08/2003WO2002036110A3 Oral self-emulsifying formulations of pyranone protease inhibitors
05/08/2003WO2002026223A3 Catecholamine pharmaceutical compositions and methods
05/08/2003WO2002024715A3 Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
05/08/2003WO2002010216A3 Proteins and nucleic acids encoding same
05/08/2003US20030088111 Protected forms of pharmacologically active agents and uses therefor
05/08/2003US20030088061 Materials and methods to modulate ligand binding/enzymatic activity of alpha/beta proteins containing an allosteric regulatory site
05/08/2003US20030087957 Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing the same
05/08/2003US20030087956 Useful in the treatment of disease mediated by the interaction between VCAM-1 and/or fibronectin and the integrin receptor alpha 4 beta 1.
05/08/2003US20030087950 New alpha-amino acid sulphonyl compounds
05/08/2003US20030087945 Sulfonylaminocarboxylic acids
05/08/2003US20030087939 Novel succinate derivative compounds useful as cysteine protease inhibitors
05/08/2003US20030087926 Substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid derivatives
05/08/2003US20030087924 Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
05/08/2003US20030087923 4-Amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases
05/08/2003US20030087922 Aryl substituted 2-aminopyrimidines and 2-aminopyridines
05/08/2003US20030087912 Aryl oxime-piperazines useful as CCR5 antagonists
05/08/2003US20030087910 E.g., O-(2-quinolinylmethyl)-N-quinaldoyl-D,L-tyrosine
05/08/2003US20030087903 Mevinolin derivatives
05/08/2003US20030087898 Opioid receptor antagonists; treating irritable bowel syndrome, drug addiction or dependency, depression, and eating disorders.
05/08/2003US20030087897 Containing carboxylic acid groups; diagnosis; prophylaxis
05/08/2003US20030087875 Hypersulfated disaccharides and methods of using the same for the treatment of inflammations
05/08/2003US20030087817 Regulation of endogenous gene expression in cells using zinc finger proteins
05/08/2003US20030087816 Anticancer, antitumor agents; genetic engineering
05/08/2003US20030087302 Detection of modulators of advanced glycation end product activity; obtain sample containing advanced glycation end product activity, incubate with peptide monitor adjustment in activity, adjustment in activity indicates modulator
05/08/2003US20030087264 Detection of regulatory response to pulsatile electromagnetic stimulus; obtain tissue sample, insert probe, apply pulsatile stimulus, detect gene expression, classify genes which are expresed
05/08/2003US20030087255 Peptides which stimulate the immune response and tissue regeneration
05/08/2003US20030087249 93870, a human G-protein coupled receptor and uses therefor
05/08/2003US20030087247 Diagnosis and treatment of inflammation and hyperactive immune conditions
05/08/2003US20030086966 Antihistamine formulations for soft gelatin dosage forms
05/08/2003US20030086939 Methods to improve immunogenicity of antigens and specificity of antibodies
05/08/2003US20030086932 For use in downmodulation or upmodulation of the immune response; for preparing an allogeinc cell for transplantation
05/08/2003US20030086921 For therapy and prophylaxis of allergic conditions, autoimmune diseases and inflammatory diseases
05/08/2003US20030086900 Method of treatment using ligand-immunogen conjugates
05/08/2003CA2756610A1 Methods for producing proteins having n-linked glycans comprising (sialyl-) lewis x or lacdinac structures
05/08/2003CA2466824A1 Pde9 inhibitors for treating cardiovascular disorders
05/08/2003CA2466424A1 Utilization of inhibitors of rho-kinases for stimulating nerve growth, inhibiting scar tissue formation and/or reducing a secondary lesion
05/08/2003CA2465874A1 Thymosin alpha 1 (ta1) peptides conjugates to polyethylene glycol (peg) polymers
05/08/2003CA2465399A1 Alkane diol derivatives as therapeutic agents for the treatment of bone conditions
05/08/2003CA2465314A1 Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
05/08/2003CA2465236A1 Substituted indoles, method for production and use thereof for the inhibition of pain
1 ... 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 ... 1172